Ionis Pharmaceuticals
IONS
363 hedge funds and large institutions have $5.6B invested in Ionis Pharmaceuticals in 2020 Q1 according to their latest regulatory filings, with 36 funds opening new positions, 106 increasing their positions, 137 reducing their positions, and 61 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
0.84% less ownership
Funds ownership: 85.83% → 84.99% (-0.84%)
7% less funds holding
Funds holding: 391 → 363 (-28)
23% less repeat investments, than reductions
Existing positions increased: 106 | Existing positions reduced: 137
23% less capital invested
Capital invested by funds: $7.29B → $5.6B (-$1.7B)
34% less call options, than puts
Call options by funds: $30.9M | Put options by funds: $46.5M
41% less first-time investments, than exits
New positions opened: 36 | Existing positions closed: 61
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$106M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$70.9M |
| 3 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$17.2M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$12.3M |
| 5 |
EC
EcoR1 Capital
San Francisco,
California
|
+$11.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$153M |
| 2 |
D.E. Shaw & Co
New York
|
-$29.2M |
| 3 |
Renaissance Technologies
New York
|
-$19.5M |
| 4 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
-$19.4M |
| 5 |
SI
Scout Investments
Kansas City,
Missouri
|
-$15.6M |
IONS Hedge Fund Activity: Q1 2020 in Review
363 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in Ionis Pharmaceuticals (IONS) for Q1 2020, worth a combined $5.6B — down 23% from $7.29B a quarter earlier.
Sellers outnumbered buyers: 61 funds closed out of IONS and 36 opened new positions — a net loss of 25 holders — while 137 trimmed existing stakes and 106 added.
The largest buyer was T. Rowe Price Associates, adding an estimated $106M. The largest seller was Wellington Management Group, cutting an estimated $153M.
- 363 institutional investors held Ionis Pharmaceuticals (IONS) as of Q1 2020, down from 391 in Q4 2019.
- Funds reported $5.6B of Ionis Pharmaceuticals stock for Q1 2020, down 23% quarter-over-quarter.
- 36 funds opened new Ionis Pharmaceuticals positions in Q1 2020 and 61 closed out, a net change of -25 holders.
- The largest Ionis Pharmaceuticals buyer in Q1 2020 was T. Rowe Price Associates, an estimated $106M added.
- The largest Ionis Pharmaceuticals seller in Q1 2020 was Wellington Management Group, an estimated $153M sold.
Based on aggregated 13F filings for Q1 2020.